NACFC 2022 | S01: Design of Clinical Trials to Evaluate Nucleotide-Based Interventions

(1:52:31)

NACFC 2022 | S03: Are CFTR Modulators Reducing Airway Infection and Inflammation?

(1:57:41)

NACFC 2022 | S25: What Is the Deal with Type 2 Diabetes and Cystic Fibrosis Related Diabetes (CFRD)

(1:48:29)

NACFC 2022 | W21: Evidence-Based Medicine: Update on Clinical Trials in Cystic Fibrosis

(1:33:55)

NACFC 2022 | S33: Tone Your Bones: Promoting Bone Health Across the Lifespan

(1:51:51)

NACFC 2022 | W22: Epidemiology and Management of Infections

(1:57:22)

NACFC 2022 | W01: PEx in the Era of Highly Effective Modulator Therapy (HEMT):How Do We Define This?

(1:35:25)

NACFC 2022 | L\u0026L06: Managing Headaches in the Cystic Fibrosis Patient

(1:20:34)

CF Foundation | NACFC 2022 Highlights

(1:2:36)

NACFC 2022 | S05: Submucosal Glands: Mucus Secretion and Defense

(1:58:21)

NACFC 2022 | S18: Reproductive Health and Parenting in the Modern Era of Cystic Fibrosis

(1:57:20)

NACFC 2022 | S22: Where Has All the Sputum Gone? Detecting and Diagnosing Infections Without Sputum

(1:58:29)

NACFC 2022 | S21: Preclinical Assessment of Novel Genetic Therapies

(1:59:13)

NACFC 2022 | S11: Delivery to the Lung: The Right Technology, the Right Cell

(2:13:44)

NACFC 2022 | DG15: Treatment for All: Unique Situations in PT Care

(1:57:28)

NACFC 2022 | DG18: Optimizing Women's Health Through Physical Therapy (PT)

(1:26:30)

NACFC 2022 | S14: Unraveling the Pathogenesis of NTM Infections in Cystic Fibrosis

(1:54:2)

NACFC 2022 | W16: Updates in Cystic Fibrosis Pharmacotherapy

(1:41:6)

NACFC 2022 | DG08: Genetics and Genetic Counseling

(2:2:57)

NACFC 2022 | DG20: Houston We Have a Problem — Challenging Cases

(2:21)